FDA Drug · D-0149-2024

Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66

Class III · Completed

Failed Dissolution Specifications

Affected lots / codes — check yours against thisLot# ME2713; Exp. 02/2025 Lot # MF8286, ML1860; Exp. 04/2025

Recalling firm: Siegfried Barbera, SL, Barbera Del Valles, N/A
Classification: Class III (unlikely to cause harm)
Status: Completed
Quantity: 2016
Distribution: Nationwide
Recall initiated: November 20, 2023
Classified: December 13, 2023
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0149-2024%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →